Notably, in a Phase I/II clinical trial reported in 2023, the combination of Panobinostat with autologous DC vaccines for recurrent glioblastoma patients achieved preliminary positive results, with 30% of patients achieving disease stability or partial remission, and treatment group patients showing marked expansion of tumor-specific CD8+ T cell populations [28]. Here, CD8A is linked to neoplasm.